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were calculated. QoL was evaluated using EQ-5D health state utility scores. Cost 
per quality adjusted life year (QALY) gained and incremental cost effectiveness 
ratio (ICER) were determined. Differences within groups were determined using 
Mann-Whitney tests. Results: Total costs for 6 months treatment with iCaPPS was 
RM790.34, while conventional care cost RM527.22. QALY for iCaPPS patients was 
0.55 (0,1.65) compared to conventional care 0.32 (0, 0.73) (z= -0.21, p= 0.84). Cost per 
QALY gained for iCaPPS was RM1436.98, conventional care was RM1647.56. The ICER 
was RM1144.00, equivalent to 3.7% of per capita GDP. Discussion: Managing post 
stroke patients using the iCaPPS protocol cost 1.5 times more than conventional 
care although QALY scores improved. conclusions: The management of post 
stroke patients in the community using iCaPPS protocol is cost effective compared 
to current conventional care in public healthcentres.
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objectives: Coronary heart disease (CHD) remains the leading cause of death in 
China, requiring long-term treatment. Angina pectoris is the most common symptom 
of CHD. Because of fewer side effects and its application in multiple pathological link 
in CHD, Chinese patent medicine continue to increase its importance in the long-
term treatment of angina pectoris. This study aimed to estimate the cost-effective-
ness of Suxiao jiuxin pill, Shexiang baoxin pill, Tongxinluo capsule and Compound 
Danshen dropping pill in the treatment of angina pectoris, to provide reference for 
reasonable clinical prescription. MethoDs: A decision-analytic model was devel-
oped to estimate the cost-effectiveness of Suxiao jiuxin pill, Shexiang baoxin pill, 
Tongxinluo capsule and Compound Danshen dropping pill from the perspective of 
the whole society with a time horizon of 4 weeks. In the model, outcome on effective-
ness was based on quantitative synthetic of Meta analysis.And cost data was mainly 
based on the published data and in combination with China’s practical situation. 
Uncertainty was investigated with probabilistic sensitivity analysis, and the expected 
value of efficient, period of treatment, drug prices and average daily dose were also 
calculated. Results: The effective rates of Suxiao jiuxin pill,Shexiang baoxin 
pill,Tongxinluo capsule and Compound Danshen dropping pill were 89.67%, 87.11%, 
85.13%, 83.71%, respectively; total costs were $62.31,$64.21,$100.29,$70.08, respec-
tively.Sensitivity analysis suggested the robustness of the results. conclusions: 
Results of the model indicate that Suxiao jiuxin pill appears to be the most cost-effec-
tive.The availability of more high-quality clinical data would allow a better adaptation 
of the model . Future research could be focused on this.
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objectives: Stroke is the third leading cause of death in developed countries. 
More than 80% of strokes were ischemic stroke. An accurate and timely diagnosis in 
ischemic stroke is crucial for treatment. CT is widely used for its quick to perform, 
easy to tolerate, and reliable for detection. However the early infarct signs on CT 
is difficult to detect and limited in its ability to identify strokes likely to be benefit 
from recanalization. MRI is more accurate in detecting ischemic stroke than CT 
due to its capability of capillary level hemodynamics and the brain parenchyma. 
However, the use of MRI is costly and timely, and not all the patient can tolerate it. 
CT perfusion (CTP) expands the role of CT by providing penumbra areas in stroke 
patients, which was defect of CT compared to MRI. The purpose of the present study 
was to evaluate the comparative cost-effectiveness of CT perfusion for selecting 
stroke patients for thrombolysis. MethoDs: We searched PubMed, Embase, The 
Cochrane Libarary, and the major medical literature databases in China, several 
professional website of health technology assessment (HTA) were also searched. We 
adapted the systematic review method to systematic evaluate the cost effectiveness 
of CT perfusion. We also have constructed a decision tree model used published 
literatures to evaluate the cost effectiveness of CT perfusion in China. Results: 
Two economic studies were inclued. The ratios of cost effectiveness of CT, CTP 
and MRI for selecting stroke patients for thrombolysis were 2983.7£/QALY, 2951.4£/
QALY and 2982.9£/QALY in UK, 100483.5$/QALY and 99406.1$/QALY just for CT and 
CTP respectively in US, and 113492.4¥/QALY, 113615¥/QALY and 120831.9¥/QALY in 
China. conclusions: The results of our comparative economic evaluation show 
that CTP were more cost effectivenes amongCT and MRI in selecting stroke patients 
for thrombolysis both in China and abroad.
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objectives: Hypertension is a major risk factor for stroke and myocardial infarction 
(MI), which imposes a substantial burden on patients, caregivers, and society. Despite 
the high financial burden, limited studies have examined the cost-effectiveness of 
hypertension treatments in Taiwan. This cost utility analysis was conducted to deter-
mine the costs and quality-adjusted life years (QALYs) associated with amlodipine 
(CCB) and valsartan (ARB) in preventing stroke and MI among Taiwanese hyperten-
sion patients. MethoDs: A Markov model was developed, consisting of six states 
including alive without stroke/MI, MI, post-MI, stroke, post-stroke, and death. We 
estimated the costs and QALYS of amlodipine and valsartan in a five-year time period. 
Effectiveness data were based on a published meta-analysis. Costs of drugs, direct 
the largest cohort study ever conducted in Thailand. Costs data were based on a Thai 
database and presented in the year of 2013. Both costs and outcomes were discounted 
with 3% annually. A series of sensitivity analyses were performed. Results: The cost-
effectiveness results showed that compared with enoxaparin, fondaparinux yielded 
cost saving (lower cost with greater effectiveness in both societal and provider per-
spectives). Total cost of major bleeding with revascularization had a great impact on 
amount of cost saved both in societal and provider perspectives. With a threshold 
of 160,000 THB (4,857.32 USD), fondaparinux showed above 95% being cost-effective 
compared with enoxaparin. conclusions: Fondaparinux might be considered as 
another cost-effective alternative compared to enoxaparin in the era of limited health 
care resources in Thailand.
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objectives: Single-pill combination therapy may be more effective compared with 
two pill approach in hypertensive patients requiring concomitant statin therapy. 
We investigated the cost-effectiveness of single-pill amlodipine/atorvastatin (SP) 
therapy compared with two-pill co-administration(TP) therapy for prevention of car-
diovascular disease (CVD) with consideration to adherence in patients with hyper-
tension using simulation model. MethoDs: Cohort simulation was performed with 
1000 hypertensive patients at an increased risk of CVD or with concomitant dyslipi-
demia. The efficacy was defined as the number of CVD prevention, which depends 
on differences in patients’ adherence to each alternative. ‘Adherence’ was defined 
as compliance to medication over 80% on proportional day covered (PDC) and ‘non-
adherence’ for the remaining. The number of cardiovascular event after TP treat-
ment was based on the ASCOT-LLA trial. The proportion of the adherent patient and 
the cardiovascular outcome differences in adherence level were searched through 
systematic review. The annual costs of medicine were included according to the 
adherence levels of each alternative. Average cost-effectiveness ratio (ACER) was cal-
culated as the cost per CVD event prevented in the cohort. All costs were described 
in 1,000 Korean won(KRW). Results: The number of CVD prevention in SP approach 
was higher than in TP approach by approximately 4cases. Total annual medication 
cost with SP approach was 209,719~225,164 KRW which was lesser than the cost in 
TP approach, 261,893~281,993KRW. ACERs in SP approach were lower than those in 
TP approach (214~231KRW vs 268~298KRW per prevented CVD event, respectively). 
SP approach reduced medication cost by around 20% per cardiovascular prevention 
case than TP approach. conclusions: SP approach is cost effective compared with 
TP approach in hypertensive patients at risk of cardiovascular event or those with 
concomitant dyslipidemia for CVD prevention.
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objectives: The iCaPPS was designed to deliver comprehensive post stroke care 
for stroke survivors in communities with limited access to specialised stroke care 
services. Rehabilitation intervention and regular screening for post stroke complica-
tions were additional features of iCaPPS compared with conventional care practices. 
A cost effectiveness analysis study was done to ascertain impact of iCaPPS on quality 
of life compared with current conventional monitoring based in public healthcen-
tres. MethoDs: A cluster randomised controlled trial on 151 post stroke patients 
from 10 selected public healthcentres in Peninsular Malaysia was done to evaluate 
quality of life (QoL) of patients managed with iCaPPS (n= 86) vs conventional care 
(n= 65) for 6 months. Costs from provider and patient perspective were calculated. QoL 
was evaluated using EQ-5D health state utility scores. Cost per quality adjusted life 
year (QALY) gained and incremental cost effectiveness ratio (ICER) were determined. 
Differences within groups were determined using Mann-Whitney tests. Results: 
Total costs for 6 months treatment with iCaPPS was RM893.75 (USD271.12), while con-
ventional care cost RM408.47 (USD123.91). QALY for iCaPPS patients was 0.55 (0,1.65) 
compared to conventional care 0.32 (0, 0.73) (z= -0.21, p= 0.84). Cost per QALY gained 
for iCaPPS was RM 1625.00 (USD492.95), while conventional care was RM1276.46 
(USD387.22). The ICER was RM2109.91 (USD640.05), equivalent to 6.84% of per capita 
GDP. conclusions: Managing post stroke patients using the iCaPPS protocol in the 
community cost 2.2 times more than conventional care although QALY scores improved. 
The management of post stroke patients in the community using iCaPPS protocol is 
cost effective compared to current conventional care in public healthcentres.
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intRoDuction: The iCaPPS was designed to deliver comprehensive post stroke 
care for stroke survivors in communities with limited access to specialised stroke 
care services. Rehabilitation intervention and regular screening for post stroke com-
plications were additional features of iCaPPS compared with conventional care prac-
tices. objectives: A cost effectiveness analysis study was done to ascertain impact 
of iCaPPS on quality of life compared with current conventional monitoring based 
in public healthcentres. MethoDs: A cluster randomised controlled trial on 151 
post stroke patients from 10 selected public healthcentres in Peninsular Malaysia 
was done to evaluate quality of life (QoL) of patients managed with iCaPPS (n= 86) vs 
conventional care (n= 65) for 6 months. Costs from provider and patient perspective 
